Vasoactive Intestinal Peptide (VIP) in CIRS Contexts
internal_protocol · expert_opinion · status: needs_provider_review
Metadata
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
Embedding: pending
File: signed link
Summary (generated — provider review required)
Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide with broad regulatory roles in immune modulation, vasodilation, and neuroendocrine signaling. In the chronic inflammatory response syndrome (CIRS) / mold-illness literature associated with Shoemaker protocols, intranasal VIP is discussed as a later-stage intervention after other corrective steps. Mechanism.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (1)
evidence_reference, mechanism, safety_reference, dosing_reference
Phenotypes: dysautonomia
Evidence claims (6) · review items (4)
regulatory · pending
Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide with broad regulatory roles in immune modulation, vasodilation, and neuroendocrine signaling.
mechanism · pending
Mechanism.
mechanism · pending
VIP acts on VPAC receptors and has anti-inflammatory and immunoregulatory effects, including modulation of T-cell responses and downregulation of pro-inflammatory cytokines.
regulatory · pending
Proponents describe normalization of regulatory markers and symptom improvement in selected CIRS patients.
safety · pending
Safety considerations.
dosing · pending
This is expert-opinion-level background organized for provider review, not a treatment recommendation or dosing guidance.
Extracted chunks (1)
140 approx tokens across 1 chunks.